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OBJECTIVE: In our country rational drug prescription
and use has not been established yet. Moreover, because
there is a lack of pharmacoeconomic research, it is hard
to point the real state of art. Use of information technolo-
gies in the control of rational prescription habits is nil.
We analyzed hypertensive patient prescriptions to evalu-
ate existing practice habits. From the prescription habit
profiles thus obtained and taking into consideration the
recent reports of JNC-VI and WHO recommendations
that are currently used in our country in medical educa-
tion, we aimed to propose an urgent need for guidelines
and hospital formularies. METHODS: 1864 prescrip-
tions were obtained from the social security systems and
the relevant data of 253 patients diagnosed as hyperten-
sion was entered to SPSS. RESULTS: The analysis of the
prescriptions revealed inappropriate initial drug therapy
in hypertension (43%). In these cases initial drug therapy
for isolated hypertension began with ACE inhibitors. Av-
erage ACE inhibitor costs $12.32 and taking Turkey’s
economic situation, they are not cost-effective. Most striking
characteristic of analyzed prescriptions was polypharmacy
(5 or 4 drugs  61%). Furthermore we observed unnec-
essary drug class switch (less then 10 days) in 36 pre-
scriptions. CONCLUSIONS: The results of our analysis
has led us to the following conclusions. Drug choice for
initial drug therapy and drug class switch is not in accor-
dance with international guidelines. Unethical promotion
(a widespread problem in Turkey) probably being the
major cause. Polypharmacy, a problem we have been try-
ing to solve since the last 15 years, still exists. By prepa-
ration and effective use of therapeutic guidelines and hos-
pital formularies both polypharmacy and irrational drug
prescription can be solved.
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OBJECTIVE: To characterize the treatment, and associ-
ated costs, of hyperlipidemia in a managed care population.
METHODS: All patients within PharMetric’s Integrated
Outcomes Database possessing a diagnosis of hyperlipi-
demia (ICD-9-CM  272.0, 272.1, 272.2, 272.4) during
1997 were eligible for study inclusion. Patients with less
than 12 months of enrollment prior to or following the
initial diagnosis, or a prescription claim for a lipid-lower-
ing agent or medical claim for a cardio/cerebrovascular
event (CVE) prior to diagnosis, were excluded from the
analysis. Patient demographics, hyperlipidemia-specific
charges, prescription claims for lipid lowering agents,
and comorbid conditions were captured for each patient
during the study period. RESULTS: 16,187 patients met
the inclusion criteria. The mean age was 51.7 years (SD 
11.5), and 59.1% were female. The most common
comorbidities were hypertension (35.3%) and diabetes
(12.5%). Only 21% of patients had a prescription claim
for a lipid-lowering agent within 12 months of diagnosis.
The most common agents were the HMG-COA reduc-
tase inhibitors, prescribed to 3030 patients (18.7%). 239
patients (1.5%) had a CVE within 12 months of diagno-
sis—the most common of which was atherosclerosis
(28.9%) followed by acute myocardial infarction (4.2%).
The incidence of CVEs was positively correlated with
age, ranging from 0.8% in patients 55 to 6.52% in pa-
tients 80 years of age. The mean hyperlipidemia-spe-
cific charges per patient were $3,047 (SD  7168) for the
year prior and $5,260 (SD  13470) for the year follow-
ing the index diagnosis. For patients having a CVE, the
mean total charges were $44,213 (SD  39787). CON-
CLUSION: Hyperlipidemia represents a substantial cost
burden to health systems. Pharmaceutical treatment, de-
spite evidence of its effectiveness, was relatively uncom-
mon in this population.
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OBJECTIVES: Databases provide aggregated and con-
founded data regarding management and cost of pulmo-
nary embolism (PE). The objective of this study was to
investigate, via patient chart analysis, the average and the
variation in medical resource use strictly related to PE pa-
tients, and to find explanatory factors for the possible
variation. METHODS: Patients with confirmed PE (n 
54) were randomly selected from 5 Belgian centres. The
centres were representative for size and region. The
charts were analyzed in detail, based on a standardized
case record form. Only medical resource use related to
the treatment of presumed and confirmed PE was in-
cluded in the analysis, with a time horizon from the day
of suspicion up to discharge. RESULTS: On average, the
management of PE is rather consistent across centres.
The total average cost of PE was equal to 3,394 Euro
(95% CI  2,762–4,027 Euro). Still, large inter-individ-
ual differences are found in the intensity of diagnosis and
follow-up. More in particular, a large variation in hospi-
tal duration is found, (average  14.6 days, Std. Dev. 
9.3), but this effect was not explained by the type of cen-
tre nor the region. The only two factors that are signifi-
cantly related with hospital duration in a multivariate re-
